<DOC>
	<DOCNO>NCT00851045</DOCNO>
	<brief_summary>The purpose study determine efficacy CT-322 comparative bevacizumab , combination irinotecan , 5-FU leucovorin second-line treatment subject metastatic colorectal cancer</brief_summary>
	<brief_title>Ph II Trial Novel Anti-angiogenic Agent Combination With Chemotherapy Second-line Treatment Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>ECOG Performance Status ( PS ) ≤1 Histologically cytologically confirm , unresectable metastatic colorectal cancer Measurable disease RECIST guideline Evidence disease progression follow firstline therapy fluoropyrimidine , oxaliplatin , bevacizumab ( ≤ 8 week since last dose ) Available paraffin embed tumor tissue Willing give whole blood sample study proteins genetic polymorphism Less 28 day elapse since major surgery time randomization Known CNS metastases Excessive risk bleeding ( include use therapeutic anticoagulation low dose aspirin ) history thrombotic embolic cerebrovascular accident Uncontrolled hypertension Clinically significant cardiovascular disease History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 6 month Serious nonhealing wound , active peptic ulcer , nonhealing bone fracture , bleed skin metastasis Known HIV Positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>